drugset
drugset / Trial / NCT00783549

A Study in Healthy Volunteers of Single Doses of Orally Administered Investigational Product to Investigate Safety, Tolerability, and Pharmacokinecs.

NCT00783549 ↗

Phase 1 Completed 76 enrolled GlaxoSmithKline
RandomizedSingle-groupSingle-blindTreatment

Summary

This study is the first study in humans to assess the safety and tolerability of various doses of GSK1292263 alone, and taken with sitigliptan.

Timeline

Start
2008-09-04
Primary completion
2009-03-31
Completion
2009-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK1292263 Small molecule — Oral

Indications

hyperlipidemia